Hargan,
who led HHS as acting secretary between October 2017 and January 2018
after Trump’s first HHS chief, Tom Price, resigned after a controversy
over his use of private aircraft, has had a much less visible role.
White House Chief of Staff Mark Meadows spoke with Hargan this week,
though their conversation did not involve any discussion of a potential
job change, said one administration official.
Three
officials pointed to Azar’s handling of Bright, the ousted vaccine
expert, as an example of his tumultuous leadership of HHS. Those
officials said Azar assured the White House that Bright had been
promoted to a new job at NIH when, in fact, Bright had been demoted from
his position leading the Biomedical Advanced Research and Development
Authority.
Pence and other aides
left the coronavirus task force meeting only to later learn Bright did
not view his job change in the same way and would be filing a
whistleblower complaint to outline the “retaliatory treatment to which
[Bright] was subjected by HHS political leadership after raising
appropriate science-based concerns about White House pressure on
treatment and vaccines related to the COVID-19 pandemic,” according to
Bright’s lawyers.
It was a
different story than the one Azar had just presented in the meeting, and
the latest blow to Azar's standing in the White House.
In
a statement, HHS characterized Bright's move as a transferring of "the
skills he has applied" at BARDA to the NIH, "as part of a bold plan to
accelerate the development and employment of novel point-of-care testing
platforms."
Since being replaced
as head of the coronavirus response on Feb. 26, Azar has made few
appearances at daily press briefings on the coronavirus fight even as
deputies like top infectious disease doctor Anthony Fauci routinely
accompany Trump and provide public updates.
Comments
Post a Comment